Home / Expertise / Life Sciences & Healthcare
Lab

Life Sciences & Healthcare

Singapore

As part of a global team with over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

Feed

Show only
20 April 2021
COV­ID-19 vac­cin­a­tion and test­ing in Singa­pore - em­ploy­ment law per­spect­ive
Vac­cin­a­tion 1. What op­tions does the em­ploy­er have to en­cour­age em­ploy­ees to be vac­cin­ated? Can the em­ploy­er provide a fin­an­cial in­cent­ive to em­ploy­ees?  Vac­cin­a­tions in Singa­pore are cur­rently be­ing...
Comparable
13 April 2021
The Fu­ture of Food: What makes Singa­pore an at­tract­ive des­tin­a­tion for...
This art­icle is pro­duced by CMS Hol­born Asia, a Form­al Law Al­li­ance between CMS Singa­pore and Hol­born Law LLC. In­tro­duc­tion Singa­pore has a bur­geon­ing Ag­ri­FoodTech eco­sys­tem. As the first coun­try glob­ally...
23 March 2021
The En­larged Board of the European Pat­ent Of­fice has giv­en a mo­ment­ous...
The En­larged Board of the European Pat­ent Of­fice heard or­al ar­gu­ments in Ju­ly 2020 con­cern­ing pat­entab­il­ity of a com­puter soft­ware in­ven­tion.  This rare event was video streamed to over 1600 pat­ent stake­hold­ers...
10 February 2021
The time seems right for In­done­sia’s new Sov­er­eign Wealth Fund 
This art­icle is pro­duced by CMS Hol­born Asia, a Form­al Law Al­li­ance between CMS Singa­pore and Hol­born Law LLC. In­tro­duc­tion In an ef­fort to pro­pel sub­stan­tial for­eign in­vest­ment in­to In­done­sia, the In­done­sian...
14 December 2020
Di­git­al health apps and telemedi­cine in Singa­pore
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? 1.1 Is it con­sidered a “med­ic­al device” or a “product”...
Comparable
18 November 2020
CMS Singa­pore fur­ther boosts cor­por­ate prac­tice with new part­ner ap­point­ment
In­ter­na­tion­al law firm CMS is de­lighted to an­nounce the ap­point­ment of Bab­ita Am­bekar as a Cor­por­ate part­ner based in the firm’s Singa­pore of­fice. Bab­ita joins from DWF where she was a part­ner and Glob­al...
10 November 2020
Belt and Road videocast: Avoid­ing and man­aging risks, plan­ning for suc­cess
Leg­al and reg­u­lat­ory is­sues are the risks most of­ten as­so­ci­ated with the Belt and Road Ini­ti­at­ive (BRI), ac­cord­ing to a re­cent CMS sur­vey. In the first videocast of our BRI series, CMS part­ners dis­cuss...
02 October 2020
BRI - View from APAC
The Asia-Pa­cific re­gion (APAC) has seen ex­tens­ive Belt and Road (BRI) in­vest­ment already, and prom­ises much more.But our sur­vey of BRI par­ti­cipants in APAC re­veals un­ex­pec­ted levels of am­bi­val­ence about some as­pects of BRI pro­jects.Can these po­ten­tial dif­fi­culties be tackled in a way that will ad­dress con­cerns about is­sues such as trans­par­ency and sus­tain­ab­il­ity, and en­cour­age the great­er in­volve­ment of in­ter­na­tion­al busi­nesses that China hopes to see? And how are the un­pre­ced­en­ted prob­lems of 2020, in­clud­ing the glob­al pan­dem­ic and trade dis­putes, af­fect­ing the pro­spects of BRI?Our APAC re­port looks at is­sues in­clud­ing:Dif­fi­culties in BRI pro­jects ex­per­i­enced by APAC par­ti­cipants, and the po­ten­tial for resolv­ing these.The ef­fects of Cov­id-19 on BRI.Mit­ig­at­ing BRI risk and man­aging dis­putes.Po­ten­tial trends in the fin­an­cing of BRI pro­jects.The sec­tors at­tract­ing the most in­terest among BRI par­ti­cipants.The im­pact of BRI 2.0.
02 October 2020
Belt and Road Ini­ti­at­ive: the view from Asia-Pa­cific
The Asia-Pa­cific re­gion has seen ex­tens­ive Belt and Road Ini­ti­at­ive (BRI) in­vest­ment already, and prom­ises much more. BRI con­tin­ues to evolve des­pite cur­rent head­winds, in­clud­ing the glob­al pan­dem­ic and...
28 September 2020
High Court con­firms that the class of in­ven­tions cre­ated by AI ma­chines...
The High Court has con­firmed that the class of in­ven­tions cre­ated by AI ma­chines is not pat­entable. The de­cision po­ten­tially leaves the door open for hu­man own­ers of AI ma­chines to list them­selves as...
18 August 2020
SAL Law Re­form Com­mit­tee Re­ports on Ar­ti­fi­cial In­tel­li­gence
The Singa­pore Academy of Law (SAL) Law Re­form Com­mit­tee (LRC) set up a Sub­com­mit­tee on Ro­bot­ics and Ar­ti­fi­cial In­tel­li­gence (Sub­com­mit­tee), to re­view and make re­com­mend­a­tions on the ap­plic­a­tion of the...
13 August 2020
Sus­tain­able food pro­gress may close glob­al reg­u­lat­ory gap
In­nov­a­tion in the sus­tain­able food sec­tor is for­ging ahead at a re­mark­able pace. Our cur­rent food sources ac­count for nearly one-third of glob­al GHG emis­sions while con­sumers are in­creas­ingly bet­ter edu­cated...